GenSight Biologics SA 2015 IR
The report outlines GenSight Biologics S.A.'s business operations, financial condition, and development pipeline for the fiscal years 2014 and 2015. The company is focused on discovering and developing novel gene therapies for neurodegenerative retinal diseases, with lead product candidates GS010 and GS030. The document includes audited financial statements prepared under both French GAAP and IFRS, showing increased research and development expenses as clinical trials progressed.
Company: GenSight Biologics SA
Sector: Professional & technical services
Country: France
Year: 2015
Type: IR
Pages: 291
Back to company
GenSight Biologics SA
Registration Document
The report outlines GenSight Biologics S.A.'s business operations, financial condition, and development pipeline for the fiscal years 2014 and 2015. The company is focused on discovering and developing novel gene therapies for neurodegenerative retinal diseases, with lead product candidates GS010 and GS030. The document includes audited financial statements prepared under both French GAAP and IFRS, showing increased research and development expenses as clinical trials progressed.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2014 - Dec 31, 2015
Fiscal Year
2015
Published
May 24, 2016
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees